Fortis Healthcare Unveils Genomic Institute, Plans to Introduce AI-driven Genomic Reporting Platform

Supported by Fortis’ clinical infrastructure and Agilus Diagnostics’ expansive national network, the institute will integrate a multidisciplinary team of medical professionals. 

Fortis Healthcare has unveiled the Fortis Institute of Genomic Medicine, an initiative to transform patient care.

Supported by Fortis’ clinical infrastructure and Agilus Diagnostics’ expansive national network, the genomic institute will integrate a team of medical professionals, including specialists in molecular hematology, oncology, neurology, pediatrics, and pathology, along with genomic scientists, bioinformaticians, and AI engineers.

Fortis also plans to introduce a genomics-based health registry alongside an AI-driven genomic reporting platform specially designed for Indian clinicians.

This platform will adhere to international standards established by ACMG (American College of Medical Genetics and Genomics), AMP (Association for Molecular Pathology), and ASCO (American Society of Clinical Oncology), ensuring compliance and clinical relevance.

Anil Vinayak, group chief operating officer, Fortis Healthcare, said, “By integrating genomics into our core offerings, we are enhancing our ability to deliver personalized, data-driven care while strengthening our clinical leadership in clinical innovation. This initiative reinforces our long-term commitment to investing in future-ready technologies that improve patient outcomes, support clinical excellence, and redefine the standards of care across the healthcare ecosystem.”

According to the company, Onco-genomics will enable clinicians to decode the genetic factors that drive cancer, facilitating the development of more effective and less harmful targeted therapies.

Further, cardio-genomics will assist in the early identification of inherited cardiac conditions, which is particularly crucial for families with a history of sudden cardiac arrest, unexplained heart failure, or congenital heart disease.

Neuro-genomics also seeks to provide new possibilities for individuals with complex neurological disorders, utilizing genetic insights to enhance diagnostic precision and personalize interventions for conditions such as epilepsy, Parkinson’s disease, and rare neurodevelopmental syndromes.

Dr Ritu Garg, chief innovation and growth officer, Fortis Healthcare said, “We recognize that the future of medicine lies in precision and personalization. This institute reflects our vision to integrate cutting-edge science with clinical excellence, enabling us to drive better patient outcomes and redefine standards of care. As leaders in the healthcare ecosystem, we are committed to fostering innovation that is scalable, sustainable, and deeply impactful."

Yash Rawat, VP & facility director, Fortis Memorial Research Institute, Gurugram added, "Genomic testing is revolutionizing the way we approach health and chronic ailments. It will be crucial in curbing non-communicable diseases by enhancing early disease detection, treatment precision, and risk assessment. Whether it’s a child with unexplained anaemia, a woman with a family history of breast cancer, or a lung cancer patient needing targeted therapy, genomics changes the game by personalizing the treatment approach. By analyzing one’s DNA, one can uncover vital information about one’s inherited risk factors, how one metabolizes medications, and one’s susceptibility to certain diseases.”

Recently, Fortis Healthcare acquired the Fortis trademark through a public auction for INR 200 Cr.

The sale was conducted following a directive from the Hon'ble Delhi High Court, which had ordered it in accordance with a previous Supreme Court judgment.

Stay tuned for more such updates on Digital Health News.